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Abstract | Through their coordinated expression and activity, the iodothyronine deiodinases 
regulate thyroid hormone economy in hypothyroidism. Once heralded as the pathway 
underpinning adequate thyroid-hormone replacement therapy with levothyroxine, the role of 
these enzymes has come into question as they have been implicated in both an inability to 
normalize serum tri-iodothyronine (T3) levels and the incomplete resolution of hypothyroid 
symptoms. These observations, some of which were validated in animal models of 
levothyroxine monotherapy, challenge the paradigm that tissue levels of T3 and thyroid-
hormone signalling can be fully restored by administration of this levothyroxine alone. The low 
serum T3 levels observed among patients receiving levothyroxine monotherapy occur as a 
consequence of relative insensitivity in hypothalamic type 2 iodothyronine deiodinase (DIO2) to 
ubiquitination. In addition, residual hypothyroid symptoms have been linked to a prevalent 
polymorphism in the DIO2 gene that might be a risk factor for neurodegenerative disease. Here 
we discuss how these novel findings underscore the clinical importance of iodothyronine 
deiodinases in hypothyroidism and how a better understanding of these enzymes might 
translate to therapeutic advances in the care of millions of patients with this condition.  
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Key points  
• Levothyroxine monotherapy at doses that normalize the serum TSH does not universally 
restore parameters of thyroid hormone economy for patients with hypothyroidism. 
• The iodothyronine deiodinases provide a cell-specific, pre-receptor mechanism that 
controls TH signalling. 
• Localized thyroid hormone signalling plays a critical role of in different areas of the 
brain, as mediated by thyroid hormone transporters and the iodothyronine deiodinases. 
• T4-induced DIO2 ubiquitination normally decreases T3 production but not in the 
hypothalamus.  
• The levothyroxine dose that normalizes serum TSH in an animal model is lower than the 
dose that normalizes serum T3, explaining the increased serum T4/T3 ratio observed in 
levothyroxine-treated patients. 
• If patients carrying the Ala92D2 polymorphism derive benefit from combination therapy 
with levothyroxine and liothyronine, then genotyping for this SNP may become a 






[H1] Introduction  
Thyroid hormones are iodinated molecules produced by the thyroid gland that regulate 
development, growth, energy homeostasis, cardiovascular systems, musculoskeletal systems 
and cognitive function. Insufficient levels of the thyroid hormones tetraiodothyronine (T4) and 
tri-iodothyronine (T3) result in hypothyroidism, a prevalent condition that affects more than 8 
million patients in the USA alone1 and 1–2% of individuals living within iodine-replete 
communities.2  
 
Over the last 150 years treatment modalities for hypothyroidism have been developed around 
thyroid hormone (TH) “replacement” through administration of thyroid gland/extracts3, which 
remained the mainstay of therapy for nearly a century. However, with the discovery in 1970 
that, in humans, iodothyronine deiodinases produce most of the circulating T3,4 clinical 
standards abruptly shifted to align with the assumption that levothyroxine monotherapy would 
maintain the pool of T4 and that a group of enzymes known as the iodothyronine deiodinases 
would provide physiologic regulation of the T3 availability to tissues.5   
 
For the past few decades, clinicians have displayed an almost dogmatic reliance upon the ability 
of the iodothyronine deiodinases to mediate conversion of T4 to T3 and so regulate the 
availability of serum levels of T3 among hypothyroid patients treated with levothyroxine.6 
However, it is now understood that ~12% of all patients treated with levothyroxine are 
biochemically euthyroid (exhibit normal serum levels of thyroid-stimulating hormone [TSH]) but 
continue to experience residual symptoms of hypothyroidism, including psychological7-9  and 
metabolic effects.10,11 This finding represents a major public-health concern given the high 
prevalence of hypothyroidism and the fact that not all parameters are restored by 
levothyroxine monotherapy. With such strong reliance upon the iodothyronine deiodinases 
and, therefore, the efficacy of levothyroxine monotherapy, clinicians were left with few options 
to explain or treat these residual symptoms.  
 
As awareness of this subpopulation of patients with hypothyroidism has improved, 
investigators have made advances into understanding the aetiology of this phenomenon. The 
serum levels of T3 might not be fully normalized among such patients owing to insufficient T4-
to-T3 conversion,12 which could explain why a minority remain symptomatic despite treatment 
with levothyroxine. Some patients demonstrate improved well-being and a treatment 
preference when co-administered levothyroxine and liothyronine;13,14 however, this issue has 
remained contentious as the majority of clinical trials failed to demonstrate an objective benefit 
of combination therapy;15 as previously reviewed.16  
 
Differences within subgroups of patients with hypothyroidism could make them more or less 
responsive to levothyroxine monotherapy versus combination therapy.13 Therefore, the 
iodothyronine deiodinases that were once almost universally accepted as the key clinical 
strategy to thyroid-hormone regulation in hypothyroidism might actually cause continued 




Here we review the physiologic role of the iodothyronine deiodinases, as well as the changes 
that occur in hypothyroidism, with particular focus on their role in preserving thyroid hormone 
economy in the brain. Recent studies indicate that unique biochemical aspects of the 
iodothyronine deiodinases in the hypothalamus prevent normalization of serum T3 in patients 
treated with levothyroxine monotherapy. In combination with a prevalent DIO2 polymorphism, 
this could also explain the insufficient symptomatic response experienced by an appreciable 
proportion of the hypothyroid population.   
 
[H1] Animal models of thyroid replacement  
Further insight into regulation of iodothyronine deiodinases and tissue-specific thyroid-
hormone signalling is required to develop new strategies to treat hypothyroidism. However, 
studies in humans are limited as they require tissue biopsy. Thus, animal models have been 
developed that provide the basis for how unique aspects of iodothyronine deiodinase 
regulation might affect different thyroid-hormone replacement therapies.17-20 
 
The applicability of such models reflects the extensive similarities in thyroid physiology 
between humans and small rodents.21 Interspecies differences exist but their interference can 
be minimized by correct experimental planning. For example, the half-lives of T4 and T3 are 
longer in humans (~1 week and 1 day, respectively) than rodents (~8 hours and 2 hours, 
respectively) and so blood and/or tissue sampling should be planned accordingly.21 
Iodothyronine deiodinases are conserved across species at the amino acid level but they exhibit 
species-specific differences in tissue distribution. Type 2 iodothyronine deiodinase (DIO2) is 
expressed in the human thyroid gland and heart but not in these tissues of the rodent.22,23 
Furthermore, DIO2 is the only activating iodothyronine deiodinase in the human brain, whereas 
both Dio2 and Dio1 are expressed in the rat brain.24,25  
 
With these differences in mind, studies in thyroidectomized rats have conclusively shown that 
only therapy with a combination of levothyroxine and liothyronine could normalize serum and 
tissue T3 levels.18,19 Similar conclusions were obtained for normalization of T3-dependent 
biological parameters, such as lipid profile, mitochondrial content and the expression of T3-
target genes, in the brains of thyroidectomized rats.17 Mouse models were also instrumental in 
the discovery that preserving the stability of serum T3 concentration is a biological priority, 
which is enforced even when Dio1 and/or Dio2 are genetically inactivated in all tissues26 or in 
specific tissues.27,28 Therefore, animal models have provided substantial advances in our 
understanding of thyroid-hormone replacement therapy. 
 
[H1] Thyroid-hormone signalling  
In humans, thyroid hormones are secreted into the circulation predominantly as a prohormone 
(T4), with only ~20% secreted as the biologically active form (T3). As shown in Figure 1, T4 and T3 
enter virtually all cells through transporters in the plasma membrane and remain in equilibrium 
between plasma and cells. Once inside a cell, T3 diffuses into the nucleus and binds to a thyroid-
hormone receptor (TR or TR) to modulate gene expression. The T3–TR complex controls 
expression of specific sets of T3-responsive genes, thus promoting T3-dependent biological 
effects. Tissues contain different combinations of TR and/or TR as well as other 
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transcriptional coregulators of the T3–TR complex. Therefore, the net effect of T3 depends on 
these combinations and is highly cell and/or tissue specific.29,30  
 
Studies in patients, animal models, and in vitro cell models with mutations in the genes 
encoding TR or TR have highlighted the mechanisms involved in the positive stimulation of 
gene transcription by T3.29 Given the free T3 concentration in the plasma (about 5x10-12M) and 
the affinity of TRs for T3 (about 1x109L/M), the ratio of occupied to unoccupied TRs is 1:1 in 
most tissues. Even when unoccupied, TRs are predominantly bound to specific cis-acting 
elements in T3-responsive genes. Unoccupied TRs exhibit high affinity for negative coregulators 
of transcription (also known as corepressors), which actively inhibits gene expression. Upon 
binding to T3, TRs lose their affinity for corepressors and gain affinity for coactivators, triggering 
T3-dependent gene transcriptional activation. Therefore, the clinical syndrome of a hypothyroid 
individual is largely the result of transcriptional repression of T3-responsive genes mediated by 
unoccupied TRs. The goal of thyroid-hormone replacement therapy is to provide sufficient T3 to 
relieve TR-mediated gene repression and to promote T3-dependent transactivation of target 
genes.29 The unique role played by the unoccupied TRs is further illustrated by the fact that 
mice with knockout of both TR genes exhibit only a mild phenotype, mainly because there is no 
transcriptional repression.29 Therefore, the intensity of thyroid-hormone signalling depends on 
the ratio between occupied and unoccupied TRs, which is a function of the plasma T3 
concentration, presence of plasma membrane transporters, iodothyronine deiodinase activity 
and (ultimately) the nuclear concentration of T3.  
 
[H2] Iodothyronine deiodinases  
Iodothyronine deiodinases are small, highly homologous, integral membrane enzymes that 
modify thyroid-hormone signalling. They comprise a single N-terminal, trans-membrane 
segment connected to a larger globular cytosolic domain with a selenocysteine-containing 
active centre embedded in a thioredoxin-like fold. The molecular structure has been modelled 
using hydrophobic cluster analysis31 and confirmed with supportive experimental data in the 
case of DIO3.32 The selenium in the active centre provides enhanced substrate affinity and a 
fast turnover rate for the deiodination reaction. 
 
Both T4 and T3 can be deiodinated, a process that results in either activation of T4 (DIO1 and 
DIO2) or inactivation of T4 and T3 (DIO3). Consequently, the intracellular environment can be 
enriched with additional T3 supplied by DIO2 (enhancing thyroid-hormone action) or depleted 
of thyroid hormones by DIO3 (dampening thyroid-hormone action; Figure 1). A key property of 
iodothyronine deiodinases in thyroid-hormone signalling is their unique subcellular localization. 
DIO2 is usually retained in the endoplasmic reticulum;33,34 however, it is also found to be closely 
associated with the cell nucleus,35 but not with the Golgi apparatus.33 Therefore, the nuclear 
environment can be greatly affected by DIO2-generated T3 owing to this physical proximity. By 
contrast, DIO1 is located in the plasma membrane; it has low affinity for T4 and so DIO1-
generated T3 rapidly diffuses from the cells and reaches the plasma without appreciably 
affecting nuclear concentrations of T3.34,36  
 
The inactivating enzyme DIO3 is generally anchored in the plasma membrane, where it is 
7 
 
internalized to become part of vesicles known as early endosomes that can be recycled back to 
plasma membrane.34,37 In the rat central nervous system, Dio3 is observed in dense-core 
vesicles of hypothalamic neurosecretory axon varicosities with the active centre containing the 
C-terminus of Dio3 at the outer surface of these organelles.38 However, this peripheral 
distribution of Dio3 can change depending on oxygen availability. After unilateral induction of 
ischaemia and hypoxia in the rat brain, Dio3 is found predominantly in the nucleus of the 
neurons in the pyramidal and granular ipsilateral layers, as well as in the hilus of the dentate 
gyrus of the hippocampal formation.39 In isolated mouse hippocampal neurons grown in culture 
and in a human neuroblastoma cell line, hypoxia redirects active DIO3 to the nucleus via the 
HSP40 pathway, a shuttle mechanism known to direct proteins to the nucleus. Preventing 
nuclear DIO3 import by HSP40 knockdown almost doubles the thyroid-hormone-dependent 
glycolytic rate and quadruples the transcription of thyroid-hormone target gene ENPP2. By 
contrast, overexpression of HSP40 increases nuclear import of DIO3 and minimizes the effects 
of thyroid hormones in cell metabolism.39 Rerouting DIO3 to the nucleus decreases thyroid-
hormone signalling and might function to reduce ischaemia-induced hypoxic brain damage. 
 
The corollary is that the activity of DIO2 and DIO3 are viewed as a cell-specific, prereceptor 
mechanism that controls thyroid-hormone signalling, the intensity of which cannot be 
predicted on the basis of circulating levels of T3.40 For example, cold and/or sympathetic 
nervous system stimulation of Dio2 expression in rat brown adipose tissue accelerates 
transcription of T3-responsive genes, such as Ucp1 and Pgc1α.41 Furthermore, ectopic 
expression of DIO3 in the human heart and brain during ischaemia or hypoxia42 lifts the T3-
dependent transcriptional footprint in these organs, curbing thyroid hormone signalling.43,44 
Although no humans have been identified with loss-of-function mutations in the iodothyronine 
deiodinases,45 a few individuals have been identified with defects in selenoprotein synthesis 
resulting in consequent reduction in DIO2 activity and possible reduction in the activities of 
DIO1 and DIO3. These patients exhibit increased serum TSH levels, increased serum T4 levels 
and low serum T3 levels, but otherwise display a mild phenotype.46 
 
[H2] Effects on brain function 
The fundamental impact of thyroid hormones on brain function was established by the striking 
link between untreated congenital hypothyroidism and developmental retardation of cognitive 
function.47-49 Myelination, neuronal and/or glial proliferation, differentiation and neuronal 
migration represent crucial targets of thyroid-hormone-mediated events in the brain.48,50,51 
Access of thyroid hormones to the brain is selective, with plasma T4 displaying greater ease of 
access than T3 because of the types of transporters expressed in the blood-brain barrier. 52,53  
 
Uptake of thyroid hormones via the blood–brain barrier and into cells inside the brain 
parenchyma is mediated by transporters, including MCT8 and OATP1C1.54-56 These transporters 
are plasma membrane proteins with multiple membrane spanning domains that have a half-life 
of several days. Although levels of Mct8 and Oatp1c1 mRNA levels are decreased in a rodent 
model of nonthyroidal illness,57 there is currently no direct evidence that quick, adaptive 
changes in the transport of thyroid hormones regulate thyroid hormone availability in the brain. 
However, the observation that patients with Allan–Herndon–Dudley syndrome express a 
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mutant MCT8 protein explained the molecular background of this rare X-linked disorder, which 
is characterized by neurological abnormalities (central hypotonia, hearing problems, rotatory 
nystagmus and spasticity) and developmental delay.58,59  
 
The link between mutations in thyroid hormone transporters and neurological symptoms 
highlights the critical importance of localized thyroid-hormone signalling in different areas of 
the brain. In contrast to the majority of tissues, a large portion of T3 in the rodent brain is 
produced locally via activation of T4. A dual-labelling approach was used to assess this process 
directly60 and the findings were later confirmed in Dio2 knockout mice that exhibited ~50% 
reductions of T3 levels in the brain.61 Thus, local metabolism of thyroid hormones (that is, via 
the DIO2 and DIO3 pathways) is currently viewed as the major factor that regulates the 
intensity of thyroid-hormone signalling in the brain. Both enzymes exhibit homeostatic 
regulation in response to changes in serum levels of thyroid hormones. The activity of DIO2 
increases but that of DIO3 decreases in the presence of low concentrations of thyroid 
hormones (for example, in conditions of hypothyroidism or iodine deficiency), a finding that has 
been interpreted largely as a mechanism that delays adverse effects of hypothyroidism to the 
brain.62,63  
 
Neurons are critically important targets of T3; however, these cells lack DIO2 and are unable to 
generate T3 via this pathway.64-66 Indeed, enrichment of Dio2 expression is detected in glial cells 
when examining the transcriptome of astrocytes, neurons and oligodendrocytes.67 
Furthermore, a >95% drop in Dio2 mRNA and activity occurred in the brain of a mouse model 
that harboured a transgene conferring glia-specific inactivation of this enzyme.28 Thus, the 
current paradigm predicts that T3 generated by DIO2 located in astrocytes acts in a paracrine 
fashion to stimulate TRs in neurons.68-70 This hypothesis has been modelled and validated in 
vitro by co-culturing human DIO2-expressing glioma cells with human neuronal cells that 
express DIO3.70 In such a system, glial-cell-generated T3 (via DIO2 activity) exerts a paracrine 
effect on the co-cultured neurons and activates T3-regulated neuronal genes. Such pathways 
might also affect thyroid-hormone signalling in vivo. For example, DIO3 is activated by HIF1-α 
under conditions of ischaemia and/or hypoxia.43 Furthermore, DIO2 activity is downregulated 
and DIO3 expression is activated by the morphogenic hedgehog protein family.71,72  
 
Logically, in responding to ischaemia or hypoxia and other cues known to regulate these 
enzymes, iodothyronine deiodinases enhance or dampen thyroid-hormone signalling in discrete 
groups of cells or areas of the brain with clear consequences. For example, in rodent models, 
Dio2 plays a role the generation of TSH-releasing hormone (Trh) and/or Tsh feedback (Figure 2). 
DIO2 is also implicated in the hypothalamic regulation of nonthyroidal illness, seasonal 
breeding in birds, and the onset of hearing in rodents.73-76 Direct evidence suggests that 
iodothyronine deiodinases play similar roles in humans. For example, in the human foetal 
hypothalamus, there is a developmental dependency and coordinated expression of DIO2 and 
DIO3 in combination with the various thyroid-hormone transporters.77  
 
In the rodent and avian retina, Dio3 dampens the actions of thyroid hormones, limiting T3 
exposure to the cones and preserving survival and/or patterning of opsins, which is required for 
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cone function.78 Some evidence supports a role for iodothyronine deiodinase-mediated thyroid-
hormone signalling in the human brain. For example, a correlation exists between the levels of 
thyroid hormones and enzyme activity in different areas of the developing human brain.79 
During recovery from intraventricular haemorrhage (IVH) among preterm infants, which 
depends on maturation of oligodendrocytes and myelination, DIO2 expression is decreased and 
DIO3 expression increased, indicating localized hypothyroidism.80 Reversing this effect with 
levothyroxine treatment promotes neurological recovery among infants and in a model of IVH 
in rabbits and, if confirmed, this approach could improve the neurodevelopmental outcome of 
preterm infants with IVH.80  
 
[H1] What changes in hypothyroidism?  
The amount of thyroid hormone entering a cell is equivalent to the amount exiting that cell, 
characterizing a state of equilibrium. Studies in animal models and human cells grown in culture 
suggest that there is the net flow of T4 and T3 that depends on the type of iodothyronine 
deiodinase expressed in each given cell type (Figure 1). The expression of DIO2 creates an 
inward net flow of T4 and an outward net flow of T3; expression of DIO3 creates inward net 
flows of both T4 and T3; and the net flow is neutral if no iodothyronine deiodinase is expressed 
40.  
 
A corollary is that iodothyronine deiodinase activity also affects circulating levels of T4 and T3. In 
humans, ~70% of the circulating T3 is produced via the extrathyroidal DIO2 pathway, whereas 
~15% originates from the DIO1 pathway. Given that DIO1 is positively regulated by T3,81 
whereas the opposite is seen for DIO2, the contribution of DIO1 to the circulating T3 pool is 
increased among patients with hyperthyroidism. Notably, DIO1 activity is inhibited by 
propylthiouracil, glucocorticoids and β blockers, which explains at least part of the clinical 
efficacy of these drugs.40  
 
Most circulating T3 is metabolized via the DIO3 pathway.82 This pathway acquires especial 
clinical relevance during pregnancy because DIO3 is highly expressed in the human placenta,83 
and therefore increases the daily requirement for patients on thyroid hormone replacement 
therapy.84 Increased expression of DIO3 is also observed in some disease states, including in the 
liver, lungs, heart and brain of patients experiencing ischaemia or hypoxia.42 In rare cases, DIO3 
is expressed in infantile haemangioma to such an extent that it inactivates T3 at a faster rate 
than the hormone can be produced (consumptive hypothyroidism).85 Similarly, treatment of 
cancer patients with the tyrosine kinase inhibitors imatinib and sunitinib is associated with the 
development of hypothyroidism, which seems to be the result of marked overexpression of 
DIO3 within the tumour cells.86 
 
Hypothyroidism is an important example of the mass effect of the iodothyronine deiodinases 
changing their levels of activity in a coordinated fashion. As a result of low thyroid hormone 
levels, the activity of DIO2 is accelerated in almost all tissues, increasing whole-body fractional 
conversion of T4 to T3 that helps preserve serum levels of T3 (the opposite is observed during 
hyperthyroidism).87 In addition, DIO3 is a T3-responsive gene and thus T3 clearance is reduced in 
hypothyroidism. These coordinated and reciprocal enzyme responses explain why measuring 
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serum T3 concentration is of little diagnostic value among patients with hypothyroidism. 
 
The DIO2-adaptive response to hypothyroidism is possible because of the unique sensitivity of 
this enzyme to its natural substrate (T4). DIO2 has a short half-life (about 60 min) that becomes 
even shorter (20 min) as a result of interacting with T4 and/or its catalytic activity.88,89 In other 
words, by converting T4 to T3, DIO2 is inactivated and degraded. This mechanism is explained by 
an 18-amino acid instability loop unique to the DIO2 protein that is located adjacent to its 
globular catalytic domain.71 This loop mediates binding to the hedgehog-inducible protein WSB-
1, a ubiquitin ligase adaptor that mediates DIO2 ubiquitination and targeting for proteasomal 
degradation.90 Truncation analyses identified a core of six amino acids within the loop as the 
minimal requirements critical for recognition of DIO2 by WSB-1.91 The loop explains the short 
half-life of DIO2, a characteristic that can be transferred between proteins if the loop is fused to 
an otherwise stable protein.33  
 
As with the other iodothyronine deiodinases, DIO2 exists as a dimer maintained by interacting 
surfaces within its transmembrane and globular cytosolic domains.92 Upon binding T4, DIO2 is 
ubiquitinated with ubiquitin chains formed at the lysine 48 position,93 which in turn inactivates 
the enzyme by interfering with globular interacting surfaces critical for dimerization and 
catalytic activity.90 This state of inactivity can be transient or permanent, depending on whether 
ubiquitinated DIO2 is reactivated by DIO2-interacting deubiquitinases (DUBs),94 or 
retrotranslocated to the cytoplasm via the p97–ATPase complex and delivered to the 
proteasomes.93 The continuous association of DIO2 with this regulatory protein complex 
supports rapid cycles of deiodination, conjugation to ubiquitin, and enzyme reactivation by 
deubiquitination, allowing tight control of thyroid-hormone action (Figure 2). 
 
[H1] Treatment of hypothyroidism  
[H2] Limitations of levothyroxine monotherapy  
Unique aspects of hypothalamic DIO2 define limitations of levothyroxine replacement therapy 
and the use of TSH as a therapeutic goal.  
 
Circulating T4 and T3 exert negative feedback on the secretion of TRH and TSH.76 In rodents, 
Tsh-secreting cells co-express Dio2;95 in the rodent hypothalamus, Dio2 is expressed in 
specialized glial cells known as tanycytes (Figure 2). These cells are located in the mediobasal 
hypothalamus, on the floor and infralateral wall of the third ventricle. Tanycytes are distributed 
from the end of the optic chiasm, along the mammillary recess, and their processes also reach 
the median eminence, outside the blood-brain barrier.64,65,76 The presence of DIO2 in both 
locations is critical for T4-mediated negative feedback.28,96 In the pituitary gland, T4 must be 
converted to T3 to suppress secretion of TSH. In the hypothalamus, it is likely that T3 generation 
via DIO2 in tanycytes negatively affects TRH expression in the paraventricular nucleus.97 
However, the full extent of the role played by DIO2 at both sites is only just starting to be 
appreciated.17 Given that DIO2 activity is increased in most tissues during hypothyroidism and 
decreased in hyperthyroidism (via ubiquitination), its presence in the median eminence and 
thyrotroph would seem counterproductive to the feedback mechanism. Thus, for years it 
remained unclear how fluctuations in plasma T4 levels could be faithfully transduced in the 
11 
 
thyrotroph and paraventricular nucleus to ultimately regulate serum TSH concentration. 95 
 
The key new element in this feedback mechanism is the observation that rat hypothalamic Dio2 
is stable and largely refractory to the levels of thyroid hormones.17 In contrast to the rest of the 
body, DIO2-mediated T4-to-T3 conversion in the hypothalamus is not accelerated during 
hypothyroidism nor is it diminished by administration of thyroid hormones or hyperthyroidism. 
Indeed, a sensitivity gradient exists in the DIO2 response to hypothyroidism and thyroid 
hormones between the hypothalamus and the rest of the brain and body,17 which is similar to 
previous observations in the rodent thyrotroph.95 The corollary of these experiments is that the 
secretion of Trh and Tsh in rodents is controlled by a steady process of DIO2-mediated T4-to-T3 
conversion, thus transducing minor changes in serum T4 levels (Figure 2). By contrast, the rate 
of Dio2-mediated T4-to-T3 conversion in the rest of the body progressively decreases with 
administration of thyroid hormones because of Dio2 ubiquitination, so that peripheral T3 
production in levothyroxine-treated hypothyroid rats is progressively decreased and self-
limiting. As a result, the dose of levothyroxine required to normalize serum TSH concentration 
is lower than the dose that normalizes serum T3. Given that the rat model reproduces the 
findings observed among patients treated with levothyroxine, it is expected that similar 
pathways in humans provide the mechanistic basis for the observation of increased serum T4:T3 
ratio in the setting of normalized serum TSH levels that are frequently observed among 
levothyroxine-treated patients.12  
 
Differences in hypothalamic DIO2 susceptibility to ubiquitination explain localized sensitivity to 
levothyroxine.17 Both in vivo studies in mice harbouring astrocyte-specific inactivation of Wsb1 
and in vitro analysis of DIO2 ubiquitination induced by different tissue extracts indicated that 
DIO2 ubiquitination in the hypothalamus is relatively less or that there is faster de-
ubiquitination when compared to other tissues. As a result, in contrast to other DIO2-
expressing tissues, the hypothalamus is wired to have increased sensitivity to T4.  
 
Hypothalamic DIO2 is also sensitive to other stimuli that play a part in the hypothalamic–
pituitary–thyroid axis, including nutritional and inflammatory signals.76 Thus, regulation of DIO2 
activity in tanycytes also integrates other signals that override the input provided by circulating 
thyroid hormone levels. For example, in the animal model of lipopolysaccharide-induced 
nonthyroidal illness there is upregulation of Dio2 in tanycytes that increases local thyroid-
hormone signalling, which in turn suppresses TRH expression despite falling serum thyroid 
hormone levels.98,99 Notably, lipopolysaccharide-mediated downregulation of Trh does not 
occur in mice with global inactivation of Dio2, indicating that this pathway is required for this 
process.70 Studies in transgenic mice indicate that mice without appreciable Dio2 expression in 
astrocytes, but with an intact tanycyte Dio2 pathway, can efficiently regulate their 
hypothalamic–pituitary–thyroid axis.28  
 
[H2] Normalization of T3 levels in hypothyroidism  
Many patients receiving levothyroxine fail to achieve serum T3 levels within the normal range 
and display elevated serum T4 levels, resulting in a high serum T4:T3 ratio.12,100,101 Although this 
phenomenon has been recognized for decades, clinicians generally adopted the hypothesis that 
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iodothyronine deiodinases would appropriately regulate the pool of available T3 at the cellular 
and tissue level, thus rendering levothyroxine-treated patients euthyroid. However, some 
investigators have questioned whether a low serum T3 level and/or a high T4:T3 ratio could have 
clinical implications. Specifically, whether this situation causes the residual symptoms 
experienced by a minority of patients treated with levothyroxine.9,102  
 
The clinical data remain contentious.15,18,19 However, studies in rats indicate that levothyroxine 
administration alone does not normalize serum Tsh, serum T3 and tissue T3 levels at the same 
time,18 and that a serum Tsh level within the normal range coexists with lowered serum and 
tissue T3 levels. These issues have were confirmed in an animal study in which 
thyroidectomized rats receiving levothyroxine monotherapy exhibited low levels of serum T3 
and a high T4:T3 ratio.17 The novelty of this study was not only that these abnormalities in 
systemic parameters were confirmed but also that tissue-specific markers of hypothyroidism 
were evaluated. Mitochondrial content and α-glycerophosphate dehydrogenase activity—both 
known markers of T3-responsiveness in the liver and skeletal muscle—were normalized in rats 
receiving levothyroxine plus liothyronine combination therapy but not in those treated with 
levothyroxine alone. In addition, serum cholesterol levels were normalized in rats receiving 
combination therapy but not in those receiving levothyroxine monotherapy.  
 
Therefore, in the rodent model, levothyroxine replacement therapy that results in a high T4:T3 
ratio and a low serum T3 level seems to exert consequences on markers of hypothyroidism at 
the tissue level (liver and skeletal muscle). The application of these findings to human studies 
will be important to determine whether levothyroxine-treated patients experience tissue-
specific hypothyroidism and, if so, whether this effect can be reversed with combination 
therapy. 
 
[H2] Thyroid-hormone homeostasis in the brain  
The plasma contributes approximately half of the T3 present in the rodent brain, whereas the 
remainder is produced locally via deiodination of T4.61 The implication is that a drop in serum T4 
or T3 levels could negatively affect thyroid-hormone signalling in the brain. However, this effect 
is largely minimized by the homeostatic actions of the iodothyronine deiodinases.63 
Accordingly, normalization of cerebral cortex, but not cerebellar, levels of T3 in levothyroxine-
treated thyroidectomized rats is achieved when circulating levels of T4 and T3 are half that of 
euthyroid control animals that did not undergo thyroidectomy.18 In addition, cerebral cortex T3 
levels remain within the normal range over a 20-fold increase in the levothyroxine infusion 
doses.  
 
These landmark studies provide the rationale for very tight control of thyroid hormone actions 
in the brain. At face value, they suggest that thyroid-hormone signalling is preserved in the 
brain of patients with mild hypothyroidism. However, the different behaviour of rat cerebral 
cortex and cerebellum confirm that thyroid-hormone signalling in the brain is highly 
compartmentalized (that is, not all brain areas behave in the same way). To address this issue, 
thyroid hormone action was studied using 16 genetic markers of T3-responsiveness in the 
cerebral cortex, cerebellum and hippocampus of thyroidectomized rats treated with either 
13 
 
levothyroxine monotherapy or levothyroxine plus liothyronine combination therapy at doses 
that normalize serum Tsh levels.17 All genetic markers were normalized in thyroidectomized 
rats receiving combination therapy, whereas 10 markers failed to be normalized in those 
receiving monotherapy, indicative of cerebral hypothyroidism.17 The animals receiving 
monotherapy exhibited lowered serum T3 levels, which might explain some of these 
observations. An additional non-exclusive explanation is that the reduction in brain Dio2 activity 
observed among levothyroxine-treated animals (caused by the elevated serum T4:T3 ratio) 
could lead to decreased T3 production via Dio2 and add to the localized hypothyroidism.17  
 
These findings challenge the idea that the impact of reduced DIO2 activity on T3 production 
following exposure to T4 is compensated by increased substrate availability, thus preserving or 
even increasing T3 production. Although logical, this rationale might not apply to all DIO2-
expressing tissue or cell types given that in a cell system in which T4 to T3 conversion via DIO2 
was monitored while cells were exposed to progressively higher T4 levels, T3 production trailed 
T4 concentration in the medium only to a limited extent.95 This was followed by an inflection 
point at which further elevations in T4 concentration reduced DIO2 activity, and T3 production 
fell abruptly; the level of T4 at the inflection point depends on the cell type, presumably 
because of differences in DIO2 ubiquitination.95 This finding is supported by the observations 
that Dio2 activity in mice with brain-specific inactivation of Wsb-1 respond differently to T4 
administration across different brain areas.17 For example, Wsb-1 mediates Dio2 inactivation in 
response to levothyroxine administration in brain areas such as the cerebral cortex and 
hippocampus, whereas in the cerebellum Wsb-1 does not mediate loss of Dio2 activity. 
Furthermore, levothyroxine-induced Dio2 inactivation is minimal (almost nonexistent), in the 
hypothalamus.  
 
[H1] Mood disorders and cognition  
To what extent do the iodothyronine-deiodinase-mediated mechanisms regulating thyroid-
hormone signalling underpin clinical phenotypes observed among patients with 
hypothyroidism? 
 
These patients exhibit variable degrees of cognitive dysfunction, lethargy, poor motor 
coordination, memory impairment, depression, and mood disorders. In addition, the efficacy of 
antidepressant agents among euthyroid individuals is potentiated when associated with the 
administration of thyroid hormone, either levothyroxine or liothyronine.103,104 Some clinical 
studies, but not all,105 indicate that residual cognitive dysfunction exists among levothyroxine-
treated patients with hypothyroidism.9,53,106,107 Whether these residual symptoms are a 
consequence of low serum levels of T3, or a high T4:T3 ratio,108,109 remains to be determined. In 
addition, whether combination therapy would restore cognitive function is an interesting 
hypothesis to be tested. 
 
Some evidence suggests that thyroid hormones act in the brain through serotonergic pathways, 
a system involved in the pathogenesis of affective disorders and response to psychotropic 
agents.110 Arising from discrete brainstem nuclei, serotonin circuits project to a range of cortical 
and subcortical brain areas, including the prefrontal cortex, hippocampus and amygdala, which 
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explains their influence on behaviours such as mood, sleep and appetite.111 MRI spectroscopy 
and PET studies confirm that thyroid hormones act in the human limbic system, with substantial 
differences observed in the posterior cingulate cortex and the inferior parietal lobe of 
hypothyroid versus hyperthyroid individuals.112,113  
 
Considering that iodothyronine deiodinases modify thyroid-hormone signalling in the rodent 
brain,114 it seems logical to assume that the activity of these enzymes might affect mood and/or 
play a role in the variability of the response of patients with depression to T3. In animal models, 
Dio2 activity in the brain is increased by antidepressants of various classes, including selective 
serotonin reuptake inhibitors.115-117 In addition, hippocampal expression of Dio2 and Dio3 is 
increased in a mouse model that is resistant to stress-induced depression and after 
antidepressant treatment in mice.108 However, a mouse with global inactivation of Dio2 exhibits 
only a mild motor phenotype and no behavioural phenotype.61,118 By contrast, a mouse with 
global inactivation of Dio3 exhibits brain hyperthyroidism, aggressive behaviour and 
indifference towards pups.119 Furthermore, there is a negative correlation between Dio3 
expression and T3 levels in the frontal cortex and hippocampus of a mouse model of depressive 
behaviour and cognitive deficits, which is partially restored by administration of 
levothyroxine.120-122  
 
The available clinical data are inconsistent for DIO2 and DIO3 but strong for DIO1, which is 
hardly expressed in the human brain.24,79 A study of 1447 individuals enrolled from the general 
population indicated that a polymorphism in DIO1, called C785T, is associated with lifetime 
depression among white females in high-risk cohorts123 and with the antidepressant efficacy of 
T3 in a trial of the selective serotonin reuptake inhibitor sertraline.124  
 
[H1] Genetic risk and brain disease  
A prevalent single nucleotide polymorphism in the DIO2 gene (which results in a single amino 
acid substitution of Thr for Ala at position 92 in DIO2, thus called Thr92AlaD2) has been 
identified,125 with estimates suggesting that ~12–36% of individuals in the general population 
are homozygous. This variant has been associated with metabolic derangements, including 
insulin resistance125,126 and type 2 diabetes mellitus.127 Furthermore, it has been implicated in 
mental and psychological disorders,45 such as mental retardation,128 bipolar disorder129 and low 
IQ.130 Conversely, Thr92AlaD2 might confer protection from recurrent depression.131 The 
clinical relevance of Thr92AlaD2 was strengthened when a large clinical trial reported that it 
correlated with reduced well-being and a preference for levothyroxine plus liothyronine 
combination therapy versus levothyroxine monotherapy among carriers with hypothyroidism.13  
 
These findings have stimulated much intrigue in the field with most initial hypotheses focusing 
on a possible defect in thyroid-hormone signalling. However, the single amino acid substitution 
associated with Thr92AlaD2 does not alter enzyme kinetics when transiently expressed in 
cells132,133 and only indirect evidence suggests that the T4-to-T3 conversion via Thr92AlaD2 
could be less in patients.134,135 Perhaps this observation is not unexpected given that the 
mutation lies not within the catalytic site but rather within the 18-amino acid loop that controls 
susceptibility to T4-induced ubiquitination of DIO2.31 The putative functional abnormality 
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associated with expression of the variant protein was defined in studies performed in a human 
embryonic kidney cell line that had been engineered to stably express this mutation. The 
protein harbouring Ala92D2 has a longer half-life than the native form (Thr92D2) and is 
ectopically located in the Golgi apparatus.35 This aberrant subcellular localization was 
associated with abnormal Golgi structure, such that circular (rather than linear or ribbon-like) 
stacks of Golgi membrane were observed. These cellular abnormalities resulted in alterations at 
the transcriptional level that were independent of DIO2-mediated T3 production given that the 
cell line studied does not express TRs136 and that the observed gene expression pattern lacked 
typical indicators of T3-responsiveness.114 Remarkably, when human cerebral cortex samples 
from patients harbouring the polymorphism were studied, there was overlap in the expression 
of 81 genes, defining a molecular fingerprint associated with the Ala92D2 variant across these 
human cell and brain models.35  
 
In addition, robust analysis of microarray data derived from the human brain samples 
demonstrated a gene expression profile reminiscent of that of neurological diseases, with 
Huntington disease being the top gene expression pathway identified.35 This finding implies 
that the polymorphism is a novel risk factor for neurodegenerative disease or impaired 
cognition, which might explain the neuropsychological impairment displayed by some patients; 
however, further studies are needed before definite conclusions can be drawn.35 In particular, it 
will be important to elucidate whether the high T4:T3 ratio observed among levothyroxine-
treated individuals with hypothyroidism12,100 might perturb the cellular abnormalities 
associated with expression of the variant protein. This relationship could explain the improved 
well-being and preference for combination therapy recorded in a subgroup of patients because 
there was no evidence of reduced thyroid-hormone signalling in the samples (T3-independent).  
 
These findings represent a step towards determination of the relationship between the cellular 
abnormalities associated with variant protein expression and the associated clinical phenotype. 
Future studies are needed to fully characterize the molecular basis for the clinical observations. 
Nevertheless, clinical trials among this subgroup could be warranted to determine whether 
hypothyroid patients harbouring the polymorphism would benefit from alternate therapeutic 
strategies. If it is rigorously demonstrated that such patients derive benefit from combination 
therapy, then genotyping for Thr92AlaD2 could become a routine component of the 




Major advances have been made in the treatment of hypothyroidism over the past century; 
however, refined therapeutic regimens might still be needed to ensure that all patients can be 
rendered asymptomatic and clinically euthyroid. Once heralded as the ultimate regulators of 
thyroid-hormone availability and the key to levothyroxine treatment efficacy, iodothyronine 
deiodinases might actually underpin the inability to normalize serum levels of TSH and T3 
among patients receiving levothyroxine monotherapy and the insufficient symptomatic 
response experienced by an appreciable proportion of the hypothyroid population. Future 
studies exploring the role of the iodothyronine deiodinases in hypothyroidism hold real promise 
16 
 
towards determining therapeutic regimens that can normalize systemic and tissue-level 
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Figure 1 | Iodothyronine deiodinases modulate thyroid-hormone signalling in T3 target cells. 
T4 and T3 enter virtually all cells via membrane transporters. They are then modified in a cell-
specific manner by DIOs to either enhance (DIO2) or diminish (DIO3) thyroid-hormone 
signalling. Consequently, the flow of T3 diffusing from the cell membrane to the nucleus is 
increased by T3(T4), which represents T3 generated locally from T4 via DIO2. By contrast, the 
DIO3 pathway decreases the flow of T3 to the nucleus by terminally inactivating T3 to T2 and T4  
to rT3 (rT3,T2). DIO2 generates T3 in a cell compartment adjacent to the nucleus. By contrast, 
DIO3 resides in the periphery of the cell in the plasma membrane and early endosomes. Once 
inside cells, T3 can diffuse to the nucleus to modulate gene expression. Abbreviations: DIO, 
iodothyronine deiodinase; T2, di-iodothyronine; T3, tri-iodothyronine; T4, tetra-iodothyronine; 
rT3, reverse tri-iodothyronine . (Adapted from BiancoLab.org.) 
 
Figure 2 | T4-induced D2 ubiquitination in thyroid hormone homeostasis.  
In response to thyroid hormone signals from the periphery and DIO2-expressing tanycytes, 
hypophysiotropic TRH-expressing neurons release TRH into the portal blood. TRH is transported 
to the anterior pituitary gland where TSH is secreted and stimulates the thyroid gland to 
produce and secrete T4 and T3. Hypothalamic T3 is generated locally by tanycytes and enters the 
systemic circulation. T3 can also be generated in the periphery via DIO1. In most peripheral 
tissues, exposure to T4 accelerates inactivation of DIO (UbDIO2) and its targeting to the 
proteasomal system; however, UbDIO2 can be reactivated and rescued from proteasomal 
destruction by deubiquitination. Peripheral deiodination is very sensitive to T4-induced DIO2 
ubiquitination: a mild elevation in the serum T4:T3 ratio favours DIO2 inactivation and decreases 
fractional T4-to-T3 conversion and peripheral T3 production. However in the hypothalamus, 
DIO2 is less susceptible to T4-induced ubiquitination. Thus, T4 signaling via DIO2-mediated T3 
production is very effective in the hypothalamus, whereas T3 production via DIO2 is easily 
inhibited in the periphery. Abbreviations: DIO, iodothyronine deiodinase; T2, di-iodothyronine; 
T3, tri-iodothyronine; T4, tetra-iodothyronine; TSH, thyroid-stimulating hormone; TRH, thyroid-
stimulating hormone releasing hormone; UbDIO2, ubiquitinated DIO2. (The figure has been 
modified from17) 
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